Solara Active Pharma Sciences: Rights Issue Funds Used as Planned in Q4 FY26

Solara Active Pharma Sciences has reported that funds raised through its recent Rights Issue were used according to plan for the quarter ending March 31, 2026. The company confirmed this to stock exchanges, stating that its Audit Committee reviewed and approved the fund utilisation statement without comments.

Company Filing Confirms Fund Use

The company informed stock exchanges that no deviations occurred in how funds from its Rights Issue were utilized during the quarter ending March 31, 2026. The total amount raised stood at Rs. 309.79 crore. Of this, Rs. 233.61 crore was directed towards repaying debt, and Rs. 112.24 crore was allocated for general corporate purposes.

Investor Confidence Boost

This confirmation is significant for investors, as it demonstrates adherence to company governance and responsible fund management. It reassures shareholders that the capital raised is being deployed as intended, helping to reduce concerns about mismanagement.

Background on the Rights Issue

Solara Active Pharma Sciences conducted its Rights Issue following an offer letter dated May 9, 2024. The aim of this fundraising was to gather approximately Rs. 300 crore to finance working capital, repay debt, and support general corporate activities.

Impact on Shareholders

Shareholders can take comfort that the company is managing funds from the recent Rights Issue in line with its stated goals. While this compliance report does not immediately alter the company's operational or financial path, it helps maintain investor confidence.

No Deviations Found

According to the latest filing and the Audit Committee's review, no issues were flagged regarding the utilisation of these funds for the quarter ended March 31, 2026.

Industry Governance Standards

Peer companies in the pharmaceutical API sector, such as Divi's Laboratories, Laurus Labs, and Aarti Drugs, also emphasize responsible fund management and compliance. Adhering to fund utilisation plans is considered a key indicator of sound corporate governance in this industry.

Fund Utilisation Details

• Total funds raised via Rights Issue: Rs. 309.79 crore (covering periods up to Q4 FY26).
• Utilised for debt repayment: Rs. 233.61 crore.
• Utilised for general corporate purposes: Rs. 112.24 crore.

Next Steps for Investors

Investors will likely continue to monitor quarterly confirmations of fund utilisation compliance. They will also watch the timeline for utilising the remaining Rs. 1.21 crore held in Monitoring Agency and Escrow accounts. Furthermore, the overall financial health and performance of Solara Active Pharma Sciences following this fund infusion will be of interest.